Extracellular vesicle-associated microRNAs in pancreatic cancer: therapeutic resistance and translational prospects
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat because of late diagnosis, desmoplasia, and multiple mechanisms of therapeutic resistance. Extracellular vesicle (EV)-associated microRNAs (miRNAs) have been implicated in communication between PDAC cells and stromal or immune populations. This mini review critically distinguishes three levels of evidence: functional delivery of EV-associated miRNAs to recipient cells, associations between vesicle-associated miRNAs and clinical phenotypes, and non-vesicular or intracellular miRNA observations that provide contextual but not direct evidence of EV-mediated effects. Mechanistic studies implicate stromal miR-21 and miR-106b, tumour-associated miR-155 and miR-210, hypoxia-associated miR-301a and miR-30b-5p, and miR-212-3p in tumour–microenvironment interactions or treatment-related phenotypes, although the strength of causal transfer evidence varies. Plasma, serum and salivary EV-miRNA signatures are being explored for liquid biopsy, but they require prospective validation. Engineered EV-mediated siRNA delivery has reached early clinical evaluation in PDAC; this must not be conflated with clinical validation of EV-based miRNA therapeutics. We integrate mechanistic, biomarker and delivery evidence, emphasizing EV nomenclature, functional-transfer controls, and translational limitations.
Authors
- Henkie Isahwan Ahmad Mulyadi Lai (ORCID: https://orcid.org/0000-0001-8516-743X)
- Chung Yen Looi (ORCID: https://orcid.org/0000-0002-4830-3495)
- Kuan Ping Ang
- Irene Chien Chien Ngu
- Kevin Burgess Phd
- Won Fen Wong
Institutions
- University of Malaya (MY)
- Taylor's University (MY)
- UCSI University (MY)
- Texas A&M University (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fonc.2026.1969651
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health